Unlocking Nucleic Acid Sensing Pathway Drug Targets - Ventus Therapeutics

Coordonnées ENG | FR

Unlocking Nucleic Acid Sensing Pathway Drug Targets avec Kelly Pike, directrice de l’immunologie et des affaires scientifiques chez Ventus Thérapeutique et Thomas Tuschl, Ph. D., professeur en biologie moléculaire de l’ARN à l’Université Rockefeller

We are on the cusp of breaking through in an area that has really faced severe challenges.
- Kelly Pike, PhD
I'm very excited about the unique opportunity that Ventus is giving us in discovering and exploiting innate immunology pathways to make new drugs.
- Thomas Tuschl, PhD